1 Association of Visual Impairment with Brain Structure

2

3 **Running title:** VI and brain structure

4

5 Authors

6 Zhuoting Zhu, MD PhD^{1*}

7 Wenyi Hu, MBBS^{1*}

8 Huan Liao, MD²

9 Danli Shi, MD³

10 Zachary Tan, MBBS⁴

11 Yifan Chen, BM BCh⁵

12 Xianwen Shang, PhD^{1,4}

13 Yu Huang, MD PhD¹

14 Xueli Zhang, PhD¹

15 Yu Jiang, MD³

16 Wei Wang, MD PhD³

17 Xiaohong Yang, MD PhD¹

18 Mingguang He, MD PhD^{1,3,4}

19

20 Affiliations

21 1. Department of Ophthalmology, Guangdong Academy of Medical Sciences,
22 Guangdong Provincial People's Hospital, Guangzhou, China.

23 2. Neural Regeneration Group, Institute of Reconstructive Neurobiology, University
24 of Bonn, Bonn, Germany.

25 3. State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun
26 Yat-sen University, Guangzhou, China.

27 4. Centre for Eye Research, University of Melbourne, East Melbourne, Victoria,
28 Australia.

29 **NOTE:** This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

30 **5. John Radcliffe Hospital, Oxford University Hospitals NHS Foundation Trust;**

30 Oxford, UK.

31

32 **Word count:** Abstract, 266; **Whole paper:** 2275.

33 **Tables:** 3; **Figures:** 0; **Supplement tables:** 2.

34

35 **Corresponding author**

36 Mingguang He, MD PhD

37 Email: mingguang.he@unimelb.edu.au

38 Xiaohong Yang, MD PhD

39 Email: syyangxh@scut.edu.cn

40 Wei Wang, MD PhD

41 Email: zoc_wangwei@yahoo.com

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60 **Abstract**

61 **Objective**

62 To investigate the association of visual impairment (VI) with brain structures in the
63 UK Biobank Study.

64 **Methods**

65 The UK Biobank Study is a large prospective study that recruited more than 500,000
66 participants aged 40-69 from 2006 to 2010 across the UK. Visual acuity (VA) of
67 worse than 0.3 LogMAR units (Snellen 20/40) was defined as VI. Structural magnetic
68 resonance imaging (MRI) data were obtained using a 3.0-T MRI imager. Volumetric
69 measures of five global brain volumes (total brain volume, total grey matter, total
70 white matter, cerebrospinal fluid (CSF), brain stem) and the volumes of seven specific
71 brain region (thalamus, caudate nucleus, basal ganglia, pallidum, hippocampus,
72 amygdala and nucleus accumbens) were included in the present analysis.
73 Multivariable linear regression was used to investigate the association of VI with
74 global and specific brain volumes.

75 **Results**

76 A total of 8976 participants free of neurological disorders at baseline assessment were
77 included for the present analysis. The prevalence of VI was 0.02% (n=181). After
78 adjusting for a range of confounding factors, VI was significantly associated with
79 decreased volumes of the total brain ($\beta = -0.12$, 95% confidence interval (CI) -0.23 to
80 0.00, $P = 0.049$), thalamus ($\beta = -0.16$, 95% CI -0.18 to -0.04, $P = 0.010$), caudate
81 nucleus ($\beta = -0.14$, 95% CI -0.27 to 0.00, $P = 0.046$), pallidum ($\beta = -0.15$, 95% CI
82 -0.27 to -0.02, $P = 0.028$) and amygdala ($\beta = -0.18$, 95% CI -0.31 to -0.04, $P = 0.012$).

83 **Interpretation**

84 We found that VI is associated with a decrease in total brain volumes and the volumes
85 of specific brain regions implicated in neurodegenerative diseases.

86

87 **Key words:** visual impairment, structural MRI, neurodegenerative diseases

88

89

90 **Introduction**

91 Neurodegenerative diseases are a major cause of cognitive impairment and mortality
92 in the ageing populations¹. The two most common neurodegenerative diseases,
93 Alzheimer's disease (AD) and Parkinson's disease (PD) affect nearly 50 million
94 people worldwide^{2,3}. With the growth of the world population and the increase in life
95 expectancy, the disease burden of neurodegenerative diseases is estimated to increase
96 substantially in the near future.^{3,4} However, very few effective treatments for
97 neurodegenerative diseases have been developed so far⁵, highlighting the importance
98 of further investigating the underlying mechanisms of these diseases to facilitate the
99 development of strategies for prevention and early detection.

100

101 As a projection of the central nerve system (CNS) via the optic nerve, the retina has
102 been described as a "window to the brain"⁶. Additionally, growing evidence has
103 reported strong associations of visual impairment (VI) with AD⁷ and PD⁸.
104 Nevertheless, the mechanisms underlying the associations between VI and
105 neurodegenerative diseases remains unknown. It has been widely recognized that
106 structural changes in the brain could play important roles in the development and
107 progression of neurodegenerative diseases⁹⁻¹². Some studies have reported that
108 structural changes in the brain, for example, decreased grey matter in the medial
109 temporal lobe, may even precede the symptom onset of neurodegenerative diseases¹³,
110 ¹⁴. Therefore, a better understanding of the relationship between VI and brain
111 structure may provide insights into the mechanisms behind the associations between
112 VI and neurodegenerative diseases. To the best of our knowledge, no study to date has
113 investigated the association between VI and brain structure in the middle-aged and
114 elderly population.

115

116 Therefore, we aim to investigate the association of VI with brain structure in a
117 large-scale community-based study.

118

Methods

Participants

The UK Biobank is a large prospective study with more than 500,000 enrolled in 2006-2010 and participants 40 to 69 years of age attended one of 22 assessment centers across the UK¹⁵. In late 2009, ocular assessments, including visual acuity (VA), refraction, intraocular pressure (IOP), corneal hysteresis (CH), optical coherence tomography (OCT) and fundus photography, were introduced to 6 centers across the UK, taken by approximately 117,175 participants¹⁶. In 2014, 100,000 original participants in the UK Biobank study were invited back for brain, heart and body imaging¹⁷. Participants (n=9310) with both VA testing and structural brain MRI available are included in the present study. For analysis of brain structure, a total of 217 individuals with self-reported neurological disorders (Supplement Table 1) and 117 with brain volumes of more than 4 standard deviations (SD) from mean values were excluded, resulting in a final sample of 8976 participants for analysis.

Standard protocol approvals, registrations, and patient consents

Access to the UK Biobank data was granted after registration. The application ID was 62443. The UK Biobank has obtained Research Tissue Bank approval from its Research Ethics Committee recommended by the National Research Ethics Service (reference 11/NW/0382). Participants provided written informed consent.

Visual Acuity Testing

Participants were tested for habitual VA based on a logarithm of the minimum angle of resolution (LogMAR) chart. The test was performed with participants at a distance of 4 meters with optical correction, if any, or at 1 meter if not being able to read. The right eye was measured first. Participants were asked to read the letter sequentially from the top to the smallest-sized letter they could reliably identify. The test was terminated if 2 letters were identified incorrectly and the total number of letters correctly identified was converted to LogMAR VA¹⁶. VA worse than 0.3 LogMAR units (Snellen 20/40) was defined as VI.

Structural MRI

Structural MRI imaging data was obtained by a 3.0-T MRI imager (Siemens Skyra, Siemens Healthcare, Erlangen, Germany) with a standard 32-channel radiofrequency receiver head coil. T1-weighted structural imaging was performed in sagittal orientation by using a three-dimensional magnetization-prepared rapid acquisition with gradient echo sequence with a resolution of $1 \times 1 \times 1$ mm, a field-of-view of $208 \times 256 \times 256$ matrix and a duration of 5 minutes¹⁷. The processing of initially released data was performed by using FSL packages (the FMRIB Software Library, Oxford, England). Structural imaging segmentation into grey matter, white matter and cerebrospinal fluid (CSF) was applied by using FAST (Automated Segmentation Tool in FMRIB) and subcortical structures were modelled by using FIRST (FMRIB's Integrated Registration and Segmentation Tool)¹⁸. MRI protocols, imaging processing and quality control are described in detail elsewhere^{17, 18}. Data output by processing pipeline were used in the present study. A total of five global brain volumes (total brain volume, total grey matter, total white matter, CSF, brain stem) and volumes of seven specific brain regions including thalamus, caudate nucleus, basal ganglia, pallidum, hippocampus, amygdala and nucleus accumbens were included. Brain volumes were standardized to z-scores.

Covariates

Factors known to be associated with brain structure were included as covariates in the present analysis¹⁹⁻²², including age at baseline assessment, sex (male/female), ethnicity (Caucasian and non-Caucasian), obtainable education (college or university degree, and others), smoking status (current/previous and never), diabetes mellitus (yes/no), hypertension (yes/no), major depression (yes/no) and body mass index (BMI).

Age at baseline assessment was categorized into three groups: 40 to 49, 50 to 59, and 60 to 69 years old. Diabetes was defined to include those participants who had

self-reported or doctor-diagnosed diabetes mellitus, were taking anti-hyperglycemic medications or using insulin or had a glycosylated hemoglobin level of $\geq 6.5\%$. Hypertension was defined to include those participants who had self-reported, or doctor-diagnosed hypertension, were taking antihypertensive drugs or had a systolic blood pressure of at least 130 mmHg or a diastolic blood pressure of at least 80 mmHg averaged over two measurements. Self-reporting and/or the score on the Patient Health Questionnaire (PHQ, the first two items) of at least 3 were used to identify participants with depression¹⁵. BMI was calculated as the weight in kilograms divided by height in meters squared (kg/m^2).

Statistical analysis

Baseline characteristics stratified by VI were reported as number and proportion for categorical data, mean and standard deviation for continuous variables. Comparisons of categorical variables were examined by chi-square test and continuous variables by unpaired t-test. Multivariable linear regression was applied to model associations of VI with total and specific brain volumes. We firstly adjusted for age and gender (model I). The Benjamin-Hochberg procedure was employed to control the false discovery rate (FDR) at the level of 5%. Ethnicity, obtainable education, smoking status, diabetes mellitus, hypertension, major depression and BMI were further adjusted for if the model I achieved $\text{FDR} < 5\%$ significance. To reduce the prominent effect of ageing on brain structure, we performed sensitivity analysis controlling for age as a continuous variable and investigated the non-linear effects of age with adjustments of age and age squared. Analyses were performed using Stata version 13 (version 14.0; StataCorp).

Data Availability Statement

All bona fide researchers could apply to UK Biobank resources for health-related research with benefit to public health. (see ukbiobank.ac.uk/register-apply).

Results

Study Sample

The present analysis included a sample of 8976 participants free of neurological disorders. The baseline characteristics of the participants are shown in Table 1. The prevalence of VI was 0.02% (n=181). Visually impaired participants were more likely to be older and of non-Caucasian ethnicity. There were no significant differences in the proportion of gender, obtainable education, smoking status, diabetes mellitus, hypertension, major depression and in the value of BMI between VI and non-VI groups.

Brain Structure

Table 2 shows global brain volumes and the volumes of specific brain regions stratified by VI status. Except for the cerebrospinal fluid, visually impaired participants had lower volumes of other global and all specific regions of the brain.

Association of VI with Brain Structure

The associations of VI with multiple brain structures are reported in Table 3. The age- and gender-adjusted regression models demonstrated that VI was associated with lower volumes of the total brain ($\beta = -0.17$, 95% confidence interval (CI) -0.29 to -0.05, $P = 0.020$), total grey matter ($\beta = -0.17$, 95% CI -0.29 to -0.05, $P = 0.021$), total white matter ($\beta = -0.16$, 95% CI -0.27 to -0.04, $P = 0.021$), brain stem ($\beta = -0.16$, 95% CI -0.28 to -0.03, $P = 0.021$), thalamus ($\beta = -0.19$, 95% CI -0.31 to -0.07, $P = 0.020$), caudate nucleus ($\beta = -0.17$, 95% CI -0.30 to -0.03, $P = 0.021$), putamen nucleus ($\beta = -0.16$, 95% CI -0.28 to -0.03, $P = 0.021$), pallidum ($\beta = -0.18$, 95% CI -0.31 to -0.04, $P = 0.021$) and amygdala ($\beta = -0.20$, 95% CI -0.34 to -0.06, $P = 0.020$). In the full-adjusted models, VI had significant negative associations with the volumes of the total brain ($\beta = -0.12$, 95% confidence interval (CI) -0.23 to 0.00, $P = 0.049$), thalamus ($\beta = -0.16$, 95% CI -0.18 to -0.04, $P = 0.010$), caudate nucleus ($\beta = -0.14$, 95% CI -0.27 to 0.00, $P = 0.046$), pallidum ($\beta = -0.15$, 95% CI -0.27 to -0.02, $P = 0.028$) and amygdala ($\beta = -0.18$, 95% CI -0.31 to -0.04, $P = 0.012$).

Sensitivity Analysis

Sensitivity analysis controlling for age as a continuous variable was performed. The significant associations of total brain volume or caudate volume with VI shown in the main analysis had only marginal significance. With respect to volumes of other global and specific regions, similar results to the main analysis were yielded (Supplement Table 2). After further adjustments for squared age, the results continued to remain similar (Supplement Table 2).

Discussion

In the present analysis, we found that visually impaired individuals had lower volumes of total brain and multiple specific regions of brain structures, including the thalamus, caudate nucleus, pallidum and amygdala. Our findings provide insights into the mechanisms underlying the association between VI and neurodegenerative diseases.

To the best of our knowledge, this is the first study to date to report the association of VI with brain structure in the middle-aged and elderly participants. A previous study investigated the effects of congenital VI on brain structure in children²³. They found defects in the development of the posterior tracts of the visual system and reduced volume of the thalamus in children with congenital VI. Limited numbers of studies have investigated the associations of ocular diseases with changes in brain structure²⁴⁻²⁶. Patients with high myopia showed altered grey matter volumes in terms of the visual pathway and limbic systems²⁴. Wang et al.²⁵ described altered brain structure (visual and non-visual cortex, lateral geniculate body and amygdala) in patients with glaucoma. Similarly, another study reported that the volume of the lateral geniculate body was negatively associated with the cup-disc ratio²⁶. Consistent with previous findings, the present analysis observed atrophy of the visual pathway (thalamus) and limbic systems (amygdala) in the visually impaired participants. Intriguingly, atrophy of pallidum and caudate, which have well-established roles in motor regulation, was also observed in participants with VI. Study population (e.g.,

age range, ethnic background, sociodemographic characteristics), study design, and statistical analysis (e.g., statistical model, covariates adjusted in the model) might explain the discrepancy in results between our study and previous studies.

Although the mechanisms behind the association between VI and brain atrophy are not clear, several proposed mechanisms may provide explanations. It has been indicated that the pathogenesis of neurodegenerative diseases could affect both peripheral visual pathways and brain structure^{27, 28}. The reduced brain volume in the hub of the visual pathway, the thalamus, may support this hypothesis^{29, 30}. Besides, the reduction in visual inputs due to VI requires significant cognitive reserve to compensate for the impaired vision and hence may increase the cognitive burden, which could subsequently increase the vulnerability of the brain to neurodegenerative pathology. This hypothesis echoed the changes in brain structures implicated in the etiology of cognitive impairment and neurodegenerative diseases (total brain, amygdala, pallidum, caudate and thalamus) observed in visually impaired participants^{28, 31-37}. Global brain atrophy has been widely observed in patients with neurodegenerative diseases³⁸. The amygdala is important in processing and enhancing emotional memory and its atrophy explains the neuropsychological symptoms in AD patients³⁹. Pallidum and caudate nucleus play important roles in the regulation of voluntary movements. Atrophies of these regions have been observed in neurodegenerative diseases characterized by predominantly motor symptoms, such as Parkinson's disease and Huntington's disease^{40, 41}.

Alternatively, the association between VI and brain atrophy may be mediated by psychological dysregulations, such as depression and social isolation. Individuals with VI were found to be at higher risks of depression and social isolation^{42, 43}. Indeed, brain volume changes in regions related to cognitive function and emotional control (e.g. hippocampus and amygdala) were previously reported in individuals with depression and social isolation^{44, 45}. Although depression is the most important risk factor for dementia and Parkinson's disease^{46, 47}, the changes in brain volumes

identified in the present study could not be entirely explained by depression, as the association between VI and brain volume reduction remained significant after adjusting for depression.

There are several strengths of our study, including the large-scale sample size, comprehensive MRI data on the total brain and specific brain structures, subjective measure of VA and comprehensive adjustments of confounding factors. However, our study also has some limitations. Firstly, due to the cross-sectional design of the study, we are unable to clarify the causality between VI and altered brain structures. Further longitudinal studies are warranted to investigate the association between VI and the progression of alterations in brain structure. Secondly, the participants recruited in the UK biobank do not represent the whole sampling population due to “healthy volunteer” selection bias⁴⁸. Nevertheless, the investigation of the association between VI and brain structure does not require full representativeness and the results retain its robustness. Lastly, residual confounding could not be completely excluded.

Conclusion

In conclusion, our study found that VI is associated with decreased volumes in the total brain and specific brain regions that are related to neurodegenerative diseases. Further studies are warranted to examine the longitudinal relationship between VI and brain structure alterations.

Abbreviations and Acronyms:

VI = visual impairment; **VA** = visual acuity; **MRI** = magnetic resonance imaging; **CNS** = central nervous system; **AD** = Alzheimer’s disease; **PD** = Parkinson’s disease; **CSF** = cerebrospinal fluid; **BMI** = body mass index; **IOP** = intraocular pressure, **CH** = corneal hysteresis; **OCT** = optical coherence tomography; **SD** = standard deviation; **FDR** = false discovery rate; **PHQ** = Patient Health Questionnaire; **LogMAR** = logarithm of the minimum angle of resolution; **CI** = confidence intervals.

327

328 **Acknowledgements:** The present work was supported by the Fundamental Research
329 Funds of the State Key Laboratory of Ophthalmology, Project of Investigation on
330 Health Status of Employees in Financial Industry in Guangzhou, China (Z012014075),
331 Science and Technology Program of Guangzhou, China (202002020049). Prof.
332 Mingguang He receives support from the University of Melbourne at Research
333 Accelerator Program and the CERA Foundation. The Centre for Eye Research
334 Australia receives Operational Infrastructure Support from the Victorian State
335 Government. The sponsor or funding organization had no role in the design or
336 conduct of this research.

337

338 **Author Contributions:**

339 Study concept and design: Zhu ZT, Hu WY, Liao H, He MG, Yang XH.
340 Acquisition, analysis, or interpretation: All authors.
341 Drafting of the manuscript: Zhu ZT, Hu WY.
342 Critical revision of the manuscript for important intellectual content: Tan Z, Chen YF,
343 Shi DL, Wang W, He MG, Yang XH.
344 Statistical analysis: Zhu ZT, Shang XW.
345 Obtained funding: He MG, Yang XH.
346 Administrative, technical, or material support: Zhu ZT, Shang XW, Wang W, He MG,
347 Yang XH.
348 Study supervision: Wang W, He MG, Yang XH.

349

350 **Potential Conflicts of Interest:** The author(s) have no potential conflicts of interest
351 in any materials discussed in this article.

352

References

1. Erkinen MG, Kim MO, Geschwind MD. Clinical Neurology and Epidemiology of the Major Neurodegenerative Diseases. *Cold Spring Harb Perspect Biol* 2018;10.
2. Collaborators GBDD. Global, regional, and national burden of Alzheimer's disease and other dementias, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. *Lancet Neurol* 2019;18:88-106.
3. Collaborators GBDD. Global, regional, and national burden of Parkinson's disease, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. *Lancet Neurol* 2018;17:939-953.
4. Alzheimer's A. 2016 Alzheimer's disease facts and figures. *Alzheimers Dement* 2016;12:459-509.
5. Mangialasche F, Solomon A, Winblad B, Mecocci P, Kivipelto M. Alzheimer's disease: clinical trials and drug development. *Lancet Neurol* 2010;9:702-716.
6. Liao H, Zhu Z, Peng Y. Potential Utility of Retinal Imaging for Alzheimer's Disease: A Review. *Front Aging Neurosci* 2018;10:188.
7. Uhlmann RF, Larson EB, Koepsell TD, Rees TS, Duckert LG. Visual impairment and cognitive dysfunction in Alzheimer's disease. *J Gen Intern Med* 1991;6:126-132.
8. Uc EY, Rizzo M, Anderson SW, Qian S, Rodnitzky RL, Dawson JD. Visual dysfunction in Parkinson disease without dementia. *Neurology* 2005;65:1907-1913.
9. Przedborski S, Vila M, Jackson-Lewis V. Neurodegeneration: what is it and where are we? *J Clin Invest* 2003;111:3-10.
10. Pini L, Pievani M, Bocchetta M, et al. Brain atrophy in Alzheimer's Disease and aging. *Ageing Res Rev* 2016;30:25-48.
11. Calabrese M, Magliozzi R, Ciccarelli O, Geurts JJ, Reynolds R, Martin R. Exploring the origins of grey matter damage in multiple sclerosis. *Nat Rev Neurosci* 2015;16:147-158.
12. Sarasso E, Agosta F, Piramide N, Filippi M. Progression of grey and white matter brain damage in Parkinson's disease: a critical review of structural MRI literature. *J Neurol* 2020.
13. Smith CD, Chebrolu H, Wekstein DR, et al. Brain structural alterations before mild cognitive impairment. *Neurology* 2007;68:1268-1273.
14. Smith CD, Andersen AH, Gold BT, Alzheimer's Disease Neuroimaging I. Structural brain alterations before mild cognitive impairment in ADNI: validation of volume loss in a predefined antero-temporal region. *J Alzheimers Dis* 2012;31 Suppl 3:S49-58.
15. Sudlow C, Gallacher J, Allen N, et al. UK biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age. *PLoS Med* 2015;12:e1001779.
16. Chua SYL, Thomas D, Allen N, et al. Cohort profile: design and methods in the eye and vision consortium of UK Biobank. *BMJ Open* 2019;9:e025077.
17. Miller KL, Alfaro-Almagro F, Bangerter NK, et al. Multimodal population brain imaging in the UK Biobank prospective epidemiological study. *Nat Neurosci* 2016;19:1523-1536.

18. Alfaro-Almagro F, Jenkinson M, Bangerter NK, et al. Image processing and Quality Control for the first 10,000 brain imaging datasets from UK Biobank. *Neuroimage* 2018;166:400-424.
19. Hamer M, Batty GD. Association of body mass index and waist-to-hip ratio with brain structure: UK Biobank study. *Neurology* 2019;92:e594-e600.
20. Rosenberg J, Lechea N, Pentang GN, Shah NJ. What magnetic resonance imaging reveals - A systematic review of the relationship between type II diabetes and associated brain distortions of structure and cognitive functioning. *Front Neuroendocrinol* 2019;52:79-112.
21. Merz EC, He X, Noble KG, Pediatric Imaging N, Genetics S. Anxiety, depression, impulsivity, and brain structure in children and adolescents. *Neuroimage Clin* 2018;20:243-251.
22. Raji CA, Ho AJ, Parikshak NN, et al. Brain structure and obesity. *Hum Brain Mapp* 2010;31:353-364.
23. Bathelt J, Dale NJ, de Haan M, Clark CA. Brain structure in children with congenital visual disorders and visual impairment. *Dev Med Child Neurol* 2020;62:125-131.
24. Huang X, Hu Y, Zhou F, et al. Altered whole-brain gray matter volume in high myopia patients: a voxel-based morphometry study. *Neuroreport* 2018;29:760-767.
25. Wang J, Li T, Sabel BA, et al. Structural brain alterations in primary open angle glaucoma: a 3T MRI study. *Sci Rep* 2016;6:18969.
26. Chen Z, Wang J, Lin F, Dai H, Mu K, Zhang H. Correlation between lateral geniculate nucleus atrophy and damage to the optic disc in glaucoma. *J Neuroradiol* 2013;40:281-287.
27. Hart NJ, Koronyo Y, Black KL, Koronyo-Hamaoui M. Ocular indicators of Alzheimer's: exploring disease in the retina. *Acta Neuropathol* 2016;132:767-787.
28. Dallaire-Theroux C, Callahan BL, Potvin O, Saikali S, Duchesne S. Radiological-Pathological Correlation in Alzheimer's Disease: Systematic Review of Antemortem Magnetic Resonance Imaging Findings. *J Alzheimers Dis* 2017;57:575-601.
29. Benedict RH, Hulst HE, Bergsland N, et al. Clinical significance of atrophy and white matter mean diffusivity within the thalamus of multiple sclerosis patients. *Mult Scler* 2013;19:1478-1484.
30. Evangelou N, Konz D, Esiri MM, Smith S, Palace J, Matthews PM. Size-selective neuronal changes in the anterior optic pathways suggest a differential susceptibility to injury in multiple sclerosis. *Brain* 2001;124:1813-1820.
31. Apostolova LG, Beyer M, Green AE, et al. Hippocampal, caudate, and ventricular changes in Parkinson's disease with and without dementia. *Movement Disorders* 2010;25:687-695.
32. Kandiah N, Tan K, Lim CCT, Venketasubramanian N. Hyperglycemic choreoathetosis: Role of the putamen in pathogenesis. *Movement Disorders* 2009;24:915-919.

33. Azevedo CJ, Pelletier D. Whole-brain atrophy: ready for implementation into clinical decision-making in multiple sclerosis? *Current Opinion in Neurology* 2016;29:237-242.
34. Möller C, Dieleman N, van der Flier WM, et al. More Atrophy of Deep Gray Matter Structures in Frontotemporal Dementia Compared to Alzheimer's Disease. *Journal of Alzheimer's Disease* 2015;44:635-647.
35. Surova Y, Nilsson M, Lätt J, et al. Disease-specific structural changes in thalamus and dentatorubrothalamic tract in progressive supranuclear palsy. *Neuroradiology* 2015;57:1079-1091.
36. Mimuro M, Yoshida M. Chameleons and mimics: Progressive supranuclear palsy and corticobasal degeneration. *Neuropathology* 2019;40:57-67.
37. Eshaghi A, Marinescu RV, Young AL, et al. Progression of regional grey matter atrophy in multiple sclerosis. *Brain* 2018;141:1665-1677.
38. Mak E, Su L, Williams GB, et al. Longitudinal assessment of global and regional atrophy rates in Alzheimer's disease and dementia with Lewy bodies. *NeuroImage: Clinical* 2015;7:456-462.
39. Horinek D, Varjassyova A, Hort J. Magnetic resonance analysis of amygdalar volume in Alzheimer's disease. *Curr Opin Psychiatry* 2007;20:273-277.
40. Y Smith MDB, E Shink, J P Bolam. Microcircuitry of the direct and indirect pathways of the basal ganglia. *Neuroscience* 1998;86:353-387.
41. Bogaard SJA, Dumas EM, Acharya TP, et al. Early atrophy of pallidum and accumbens nucleus in Huntington's disease. *Journal of Neurology* 2010;258:412-420.
42. Cosh S, Hanno T, Helmer C, Bertelsen G, Delcourt C, Schirmer H. The association amongst visual, hearing, and dual sensory loss with depression and anxiety over 6 years: The Tromsø Study. *International Journal of Geriatric Psychiatry* 2017;33:598-605.
43. Coyle CE, Steinman BA, Chen J. Visual Acuity and Self-Reported Vision Status. *Journal of Aging and Health* 2016;29:128-148.
44. Pandya M, Altinay M, Malone DA, Anand A. Where in the Brain Is Depression? *Current Psychiatry Reports* 2012;14:634-642.
45. Düzel S, Drewelies J, Gerstorf D, et al. Structural Brain Correlates of Loneliness among Older Adults. *Scientific Reports* 2019;9.
46. Jorm AF. Is Depression a Risk Factor for Dementia or Cognitive Decline? *Gerontology* 2000;46:219-227.
47. Gustafsson H, Nordstrom A, Nordstrom P. Depression and subsequent risk of Parkinson disease: A nationwide cohort study. *Neurology* 2015;84:2422-2429.
48. Fry A, Littlejohns TJ, Sudlow C, et al. Comparison of Sociodemographic and Health-Related Characteristics of UK Biobank Participants With Those of the General Population. *American Journal of Epidemiology* 2017;186:1026-1034.

479

480 Table 1. Baseline Characteristics of Study Participants Stratified by Visual
481 Impairment Status.

Baseline Characteristics	Total	VI Group	Non-VI Group	P Value
N	8976	181	8795	-
Age, No. (%)				0.004
40 to 49	2175 (24.2)	25 (13.8)	2150 (24.5)	
50 to 59	3649 (40.7)	81 (44.8)	3568 (40.6)	
60 to 69	3152 (35.1)	75 (41.4)	3077 (35.0)	
Gender, No. (%)				0.205
Female	4740 (52.8)	104 (57.5)	4636 (52.7)	
Male	4236 (47.2)	77 (42.5)	4159 (47.3)	
Ethnicity, No. (%)				<0.001
Caucasian	8525 (95.0)	161 (89.0)	8364 (95.1)	
Non-Caucasian	451 (5.02)	20 (11.1)	431 (4.90)	
Educational Level, No. (%)				0.964
College or university degree	4230 (47.1)	85 (47.0)	4145 (47.1)	
Others	4746 (52.9)	96 (53.0)	4650 (52.9)	
Smoking status, No. (%)				0.521
Never/former	5525 (61.7)	114 (64.0)	5411 (61.7)	
Current	3425 (38.3)	64 (36.0)	3361 (38.3)	
BMI, mean (SD), kg/m ²	26.6 (4.22)	26.5 (4.09)	26.6 (4.23)	0.745
Diabetes mellitus, No. (%)				0.957
No	8672 (96.6)	175 (96.7)	8497 (96.6)	
Yes	304 (3.39)	6 (3.31)	298 (3.39)	
Hypertension, No. (%)				0.833
No	2664 (29.7)	55 (30.4)	2609 (29.7)	
Yes	6312 (70.3)	126 (69.6)	6186 (70.3)	
Depression, No. (%)				0.916

No	8300 (92.5)	167 (92.3)	8133 (92.5)
Yes	676 (7.53)	14 (7.73)	662 (7.53)

Abbreviations: VI = visual impairment, BMI = body mass index, SD = standard deviation.

482

483

484

485 Table 2. Brain Volume of Study Participants Stratified by Visual Impairment Status.

Brain Volume ^a	VI Group	Non-VI Group	P Value
Global volume			
Total brain volume	-0.27 (-0.41, -0.13)	0.01 (-0.02, 0.03)	<0.001
Total grey matter	-0.28 (-0.42, -0.13)	0.01 (-0.02, 0.03)	<0.001
Total white matter	-0.23 (-0.37, -0.09)	0.00 (-0.02, 0.03)	0.002
Brain stem	-0.20 (-0.34, -0.06)	0.00 (-0.02, 0.02)	0.008
Cerebrospinal fluid	0.08 (-0.07, 0.23)	-0.00 (-0.02, 0.02)	0.300
Specific region volume			
Thalamus	-0.31 (-0.45, -0.17)	0.01 (-0.01, 0.03)	<0.001
Caudate nucleus	-0.22 (-0.36, -0.08)	0.00 (-0.02, 0.03)	0.003
Putamen nucleus	-0.26 (-0.40, -0.11)	0.01 (-0.02, 0.03)	<0.001
Pallidum	-0.23 (-0.37, -0.09)	0.00 (-0.02, 0.03)	0.002
Hippocampus	-0.20 (-0.34, -0.05)	0.00 (-0.02, 0.02)	0.007
Amygdala	-0.23 (-0.37, -0.09)	0.00 (-0.02, 0.03)	0.002
Nucleus accumbens	-0.23 (-0.37, -0.09)	0.00 (-0.02, 0.03)	0.002

^a Brain volumes were standardized to z-scores.

486

487

488

489 Table 3. Associations of VI with Brain Volume.

Brain Volume ^a	Age- and Gender-Adjusted Model		Multivariable Model ^c	
	β (95% CI)	P Value ^b	β (95% CI)	P Value
Global volume				
Total brain	-0.17 (-0.29, -0.05)	0.020	-0.12 (-0.24, -0.00)	0.049
Total grey matter	-0.16 (-0.29, -0.04)	0.021	-0.11 (-0.23, 0.01)	0.081
Total white matter	-0.15 (-0.27, -0.03)	0.021	-0.12 (-0.24, 0.00)	0.055
Brain stem	-0.16 (-0.29, -0.02)	0.021	-0.12 (-0.25, 0.01)	0.070
Cerebrospinal fluid	0.03 (-0.10, 0.15)	0.794	-	-
Specific region volume				
Thalamus	-0.20 (-0.33, -0.07)	0.020	-0.17 (-0.29, -0.04)	0.010
Caudate nucleus	-0.16 (-0.30, -0.03)	0.021	-0.14 (-0.28, -0.00)	0.046
Putamen nucleus	-0.16 (-0.29, -0.03)	0.021	-0.12 (-0.25, 0.01)	0.062
Pallidum	-0.17 (-0.31, -0.03)	0.021	-0.16 (-0.29, -0.02)	0.028
Hippocampus	-0.13 (-0.26, 0.01)	0.103	-	-
Amygdala	-0.20 (-0.34, -0.06)	0.020	-0.18 (-0.32, -0.04)	0.012
Nucleus accumbens	-0.14 (-0.27, -0.00)	0.086	-	-

^a Brain volumes were standardized to z-scores.

^b Corrected for multiple comparisons.

^c Adjusted for age, sex, ethnicity, obtainable education, smoking status, diabetes mellitus, hypertension, major depression and body mass index.

490

491

492